Iron-deficiency Clinical Trial
Official title:
Defining the Serum Ferritin Concentration in Kenyan Women at Which the Body Senses Iron Depletion and Begins to Upregulate Iron Absorption
NCT number | NCT05266703 |
Other study ID # | PILLAR |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | February 18, 2022 |
Est. completion date | June 30, 2023 |
Verified date | January 2024 |
Source | Swiss Federal Institute of Technology |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The serum or plasma ferritin concentration (referred to hereafter as ferritin) is the most widely used indicator to detect iron deficiency and a low ferritin indicates depleted iron stores. However, the threshold ferritin that defines iron deficiency remains unclear and diagnostic ferritin cutoffs from expert groups vary widely. Our study aim is to define the ferritin in Kenyan young women at which the body senses iron depletion and begins to upregulate iron absorption from the diet; this approach could provide a functionally defined threshold of iron deficiency in Sub-Saharan African women.
Status | Completed |
Enrollment | 1000 |
Est. completion date | June 30, 2023 |
Est. primary completion date | June 30, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 28 Years |
Eligibility | Inclusion Criteria: - Age 18-28 y, not pregnant or lactating - Body weight <75 kg - body mass index (BMI) between 17 and 25 kg/m2 - No acute illness/infection (self-reported) - No metabolic or gastrointestinal disorders (self-reported) - No use of medications affecting iron absorption or metabolism during the study - No intake of mineral/vitamin supplements 2 weeks prior to the first study visit and during the study |
Country | Name | City | State |
---|---|---|---|
Kenya | Msambweni County Referral Hospital | Msambweni |
Lead Sponsor | Collaborator |
---|---|
Swiss Federal Institute of Technology | Jomo Kenyatta University of Agriculture and Technology |
Kenya,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fractional iron absorption | shift in iron isotopic ratios measured in red blood cells | Day 14 | |
Secondary | Plasma Ferritin | Day 0 | ||
Secondary | Plasma Ferritin | 4 months after isotope administration | ||
Secondary | Plasma Ferritin | 8 months after isotope administration | ||
Secondary | Plasma Ferritin | 12 months after isotope administration | ||
Secondary | soluble transferrin receptor | Day 0 | ||
Secondary | soluble transferrin receptor | 4 months after isotope administration | ||
Secondary | soluble transferrin receptor | 8 months after isotope administration | ||
Secondary | soluble transferrin receptor | 12 months after isotope administration | ||
Secondary | C-reactive protein | Day 0 | ||
Secondary | C-reactive protein | 4 months after isotope administration | ||
Secondary | C-reactive protein | 8 months after isotope administration | ||
Secondary | C-reactive protein | 12 months after isotope administration | ||
Secondary | alpha-1-glycoprotein | Day 0 | ||
Secondary | alpha-1-glycoprotein | 4 months after isotope administration | ||
Secondary | alpha-1-glycoprotein | 8 months after isotope administration | ||
Secondary | alpha-1-glycoprotein | 12 months after isotope administration | ||
Secondary | Hemoglobin | Day 0 | ||
Secondary | Hemoglobin | 4 months after isotope administration | ||
Secondary | Hemoglobin | 8 months after isotope administration | ||
Secondary | Hemoglobin | 12 months after isotope administration | ||
Secondary | Plasma Hepcidin | Day 0 | ||
Secondary | Isotopic composition of red blood cells | shift in iron isotopic ratios measured in red blood cells | 4 months after isotope administration | |
Secondary | Isotopic composition of red blood cells | shift in iron isotopic ratios measured in red blood cells | 8 months after isotope administration | |
Secondary | Isotopic composition of red blood cells | shift in iron isotopic ratios measured in red blood cells | 12 months after isotope administration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04949165 -
Bloodsafe Ghana- Iron and Nutritional Counseling Strategy Pilot Study
|
N/A | |
Terminated |
NCT03218384 -
Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency
|
Phase 2 | |
Active, not recruiting |
NCT03516734 -
Iron-fortified Lentils to Improve Iron (Fe) Status in Bangladesh
|
N/A | |
Completed |
NCT03572010 -
Stable Iron Isotope Method in HIV+ and HIV- Children
|
N/A | |
Active, not recruiting |
NCT03703726 -
Iron Absorption From Fortified Extruded Rice Using Different Extruding Temperatures.
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Not yet recruiting |
NCT05395468 -
Diagnosis of Iron Deficiency by Artificial Intelligence Analysis of Eye Photography.
|
||
Withdrawn |
NCT03800446 -
Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood
|
N/A | |
Not yet recruiting |
NCT03353662 -
Sub Regional Micronutrient Survey in Ethiopia
|
||
Completed |
NCT03819530 -
Child of Urban Poverty Iron Project (CUPIP) - A Pilot Study
|
N/A | |
Recruiting |
NCT04144790 -
Impact of Iron Supplementation Treatment on Brain Iron Concentrations
|
||
Completed |
NCT03957057 -
Intravenous Iron Carboxymaltose, Isomaltoside and Oral Iron Sulphate for Postpartum Anemia
|
Phase 3 | |
Completed |
NCT03642223 -
Central and Peripheral Adiposity and Iron Absorption
|
N/A | |
Not yet recruiting |
NCT05407987 -
Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)
|
Phase 3 | |
Withdrawn |
NCT03873584 -
Improvement of Fatigue Symptoms in the Iron Deficiency Anemia With Iron Succinylate Therapy
|
||
Enrolling by invitation |
NCT03897673 -
Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas
|
N/A | |
Completed |
NCT04359368 -
Characteristics of Patients With Hypersensitivity Reactions to Intravenous Iron Infusions
|
||
Active, not recruiting |
NCT04778072 -
A Clinical Study on Adherence and Efficacy of Different Doses of Active Iron in Treatment Resistant Subjects
|
N/A | |
Enrolling by invitation |
NCT05750940 -
Oxidative Skeletal Muscle Metabolism in Chronic Heart Failure Patients With and Without Iron Deficiency
|
||
Recruiting |
NCT05126901 -
Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years
|
Phase 3 |